Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer

Basit Öğe Kaydı
dc.authorwosidmenekşe, serkan/HNP-3265-2023
dc.contributor.authorMenekse, S.
dc.contributor.authorKut, E.
dc.contributor.authorAlmuradova, E.
dc.date.accessioned2024-08-25T18:38:52Z
dc.date.available2024-08-25T18:38:52Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractOBJECTIVE: This study aimed to evaluate the prognostic significance of the LDH-to-albumin ratio (LAR) in patients with non-small cell lung cancer (NSCLC) receiving nivolumab monotherapy. We comprehensively analyzed the associations between LAR and clinical parameters, progression-free survival (PFS), and overall survival (OS) to identify reliable biomarkers for treatment selection. PATIENTS AND METHODS: A total of 144 patients with metastatic NSCLC treated with nivolumab were included. Patient characteristics, including demographic data, smoking history, albumin, lactate dehydrogenase (LDH) levels, and LAR were recorded. Univariate and multivariate analyses were conducted to determine the associations between these factors and PFS/OS. The LAR cut-off value was determined using receiver- operating characteristics (ROC) curve analysis. RESULTS: The median overall survival was 14.2 months, and the median progression-free survival was 5.28 months. Univariate analysis showed that smoking, ECOG performance score, brain metastasis, PD-L1 level, nivolumab treatment line, albumin, hemoglobin, LDH levels, platelet count, monocyte count, lymphocyte count, and LAR were associated with PFS. In the multivariate analysis, only LAR remained significantly associated with PFS. For overall survival, smoking, ECOG performance score, albumin level, LDH level, platelet count, monocyte count, lymphocyte count, brain metastasis, LAR, nivolumab treatment line, and PD-L1 level were significant in the univariate analysis. Albumin level, ECOG performance score, and LAR were independently associated with overall survival in the multivariate analysis. CONCLUSIONS: The LAR, reflecting tumor burden, tumor hypoxia, immune response, nutritional status, and systemic inflammation, emerged as a potential prognostic biomarker in NSCLC receiving nivolumab monotherapy. This study highlights the importance of considering multiple factors in treatment decisions and supports the need for personalized approaches in NSCLC immunotherapy. Further research is needed to validate the utility of LAR as a predictive biomarker in this patient population.en_US
dc.identifier.endpage94en_US
dc.identifier.issn1128-3602
dc.identifier.pmid37869953en_US
dc.identifier.startpage86en_US
dc.identifier.urihttps://hdl.handle.net/11454/101177
dc.identifier.volume27en_US
dc.identifier.wosWOS:001091509100013en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectLactate dehydrogenase-to-albumin ratioen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectNivolumaben_US
dc.subjectProgrammed cell death-ligand 1en_US
dc.subjectSafetyen_US
dc.subjectSuppressionen_US
dc.subjectEfficacyen_US
dc.titleElevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu